Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

Tenmile and Novo Holdings are core investors Cristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of Directors Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organisms SAN FRANCISCO,…

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks